Revised 16 September 2026 · v1.1.0 · what changed

On 5 December 2025, Indian pharma trade press reported a "₹60,000 crore ($7 billion) API push" to cut import dependence on critical pharmaceutical ingredients. It is a real number, but not a real single thing: it is the sum of at least six schemes that mostly predate that announcement, several running since 2020, plus the private investment they're designed to attract on top of their own government outlay. None of that makes the push fictitious — but reporting it as one December 2025 decision obscures both how long this has actually been building and how modest the flagship scheme's results still are next to the dependency it was built to fix.

1. What the ₹60,000 crore is actually made of

Add the government outlays alone and the total is roughly ₹43,000–44,000 crore, not ₹60,000 crore. The gap is private and state co-investment the schemes are structured to pull in on top of the public money — visible already in the Bulk Drugs PLI's own numbers below, where actual investment has run ahead of the government's own committed figure. That is a legitimate way to report a policy push's total scale, but it is a different claim from "government spent ₹60,000 crore in December 2025," which is not what happened.

The Bulk Drug Parks line in that table needs its own caveat, sourced from this blog's own separate reading of the government's Parliament data: five-plus years after Cabinet approval, zero of the three parks (Andhra Pradesh, Gujarat, Himachal Pradesh) are in commercial production. The ₹3,000cr central outlay and the combined ~₹6,300cr figure describe money committed to shared infrastructure, not capacity that exists yet.

2. The Bulk Drugs PLI's actual trend line

Unlike the roll-up figure, this scheme has a genuine time series, and it shows real if incremental movement across three snapshots reported between September 2025 and March 2026:

3. Reconciling this against the number that actually matters

This blog's earlier reporting already established the scale of what these schemes are up against: 43.45% of India's pharma imports by value still come from China, and China supplies 70% or more of 97 distinct active ingredients. Against a China import bill running in the billions of dollars a year, ₹2,190–2,192 crore of cumulative import substitution since 2020 is real progress on individual molecules — the scheme has localised Penicillin G, Clavulanic Acid, Rifampicin and Atorvastatin among others — but it has not moved the 43.45% headline number, and nothing in this round of figures suggests it's about to. The ₹60,000 crore figure describes ambition and total policy scale; the Bulk Drugs PLI's own numbers describe the actual pace of substitution, and the two are not the same claim.

4. The other half of the picture: India's global API share is rising anyway

Separately from import substitution, India's position as a global API supplier — a different metric from how import-dependent India's own domestic industry is — has been improving. India's API market is estimated at roughly $15.28 billion in 2026, forecast to reach $22.18 billion by 2031 at a 7.74% CAGR, and industry estimates put India's share of global API supply climbing toward 30–35% as China's own share is reported falling from around 45% in 2022 toward roughly 30%. These are not contradictory findings sitting next to the 43.45% China-dependency figure: one measures how much of the world's API manufacturing capacity sits in India, the other measures how much of India's own specific import basket still comes from China. A country can plausibly gain global manufacturing share in APIs generally while remaining acutely dependent on a single supplier for a specific subset of molecules — exactly the "formulation superpower built on an intermediate-goods dependency" pattern this blog has described before.

Sources: PIB press releases on "Strengthening pharmaceutical self-reliance" and the PRIP call for proposals; newsonair.gov.in (Akashvani/Prasar Bharati) coverage of Union Minister J.P. Nadda's 10 March 2026 Rajya Sabha statement (PLI figures, ₹41,500cr API export figure, the "pharmacy to laboratory" framing) and the Biopharma SHAKTI mission briefing; Elets eHealth's December 2025 reporting on the ₹60,000cr figure; Policy Circle, India Briefing, IBEF and India Pharma Outlook coverage of individual scheme outlays (PRIP, Bulk Drug Parks, Medical Devices PLI, Biopharma SHAKTI) used to reconstruct the roll-up in Section 1; Mordor Intelligence-class market-sizing reports for the $15.28bn/$22.18bn API market figures and the India/China global-share estimates. This blog's own "India Cannot Sell ‘China-Free’ Medicine While Importing 43% of What's In It," whose 43.45%/97-API figures are reused directly, not re-derived, and "Five Years and ₹25,000 Crore Later, China Still Supplies Three-Quarters of India's Drug-Making Ingredients," whose "0 of 3 Bulk Drug Parks in commercial production" figure is reused the same way, found via a same-day archive cross-check with tools/research_crosscheck.py rather than in this piece's original research. The Sept 2025 and Dec 2025 PLI snapshots came from different secondary aggregators reporting the same underlying scheme, not two independent counts; minor cross-source rounding (₹2cr on sales, ₹2cr on import substitution) is treated as noise, not a real change.

Related on this blog

See also: India Cannot Sell “China-Free” Medicine While Importing 43% of What's In It · Five Years and ₹25,000 Crore Later, China Still Supplies Three-Quarters of India's Drug-Making Ingredients · Ethanol Freed Up Refinery Capacity for Petrochemicals. The Pharma Chain Hasn't Seen Much of It Yet. · India's Semaglutide Patent Cliff: 26 Brands in Weeks, a Price War, and a Government Crackdown.

About this article: Researched, written and edited by Umashankar Triplicane Dwarakanathan, with AI research assistance; every figure is meant to trace to the primary source cited. See the Editorial Policy for how sourcing, AI use and corrections work.